

Supplementary Material




Figure S1. Forest plot of SUA-lowering effect of allopurininol [42,43,45–63].




Figure S2. Forest plot of SUA-lowering effect of febuxostat [42,43,45–47,51,64–70].




Figure S3. Forest plot of SUA-lowering effect of topiroxostat [49,50,63,71–74].




Figure S4. Funnel plot of AD for febuxostat monotherapy vs. allopurinol 300 mg daily [42–45].

Table S1. Exclusion of the Trial Arms in the Urate-Lowering Therapy Drug Analysis.

Uric Lowering Therapy Drugs	Collected Number of Trial Arms	Reasons for Exclusion of the Trial Arms						Included Number of Trial Arms in the Final Analysis
		Normal Range of Serum Uric Acid	Dosage Other than Once Daily (no QD)	Dose Titration	Uric Lowering Data Availability	CKD Diagnosis Availability	Placebo or Colchicine Trial Arms	
Allopurinol	53	5	5	8	5	1		29
Benzbromarone	16		4		3	5		4
Febuxostat	48	6	1	2	11			28
Lesinurad	9	7			1			1
Pegloticase	11	4	7					0
Probenecid	4	1	1			1		1
Rasburicase	22	8	1	1	12			0
Topiroxostat	21	1	4					16
Combination of two ULT drugs	26	9	1	9	3			4
Colchicine	2						2	0
Placebo	23						23	0